Clinical trials: malaria
Malaria, Burkina Faso
Evaluation of Three Artemisinin-based Combinations for the Treatment of Uncomplicated Malaria in Childreen in Burkina Faso (CHIMIO2)
Bakground In Burkina Faso, since the adoption of this new malaria treatment policy in 2005, several studies evaluating the efficacy and tolerance of ACTs have been carried out by different research teams at different sites…
- Trial name
- CHIMIO2 (NCT04778813)
- Testing
- Artemether-lumefantrine
- Where
- Burkina Faso
- Volunteers
- 1,050 people
- Sponsor
- Centre national de recherche et de formation sur le paludisme
Malaria
Safety of and Immune Response to a Malaria Vaccine (MSP1 42-C1) With or Without CPG 7909 Adjuvant
The purpose of this study is to determine the safety of and immune response to a preventive malaria vaccine, MSP1 42-C1/Alhydrogel, in healthy adults.
- Trial name
- NCT00320658
- Testing
- MSP1 42-C1/Alhydrogel, CPG 7909
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Pregnancy
Efficacy and Safety of IPTp-DP Versus IPTp-SP in Malawi
This study aims to compare the efficacy of monthly IPTp-DP with monthly IPTp-SP to determine if IPTp-DP is associated with a reduction in malaria infection at delivery among HIV-negative women in an area with high levels of SP…
- Trial name
- STOPMIP-MW (NCT03009526)
- Testing
- Sulfadoxine-pyrimethamine, dihydroartemisinin-piperaquine
- Where
- Malawi
- Volunteers
- 602 people, healthy volunteers welcome
- Sponsor
- Kamuzu University of Health Sciences
Malaria
Controlled Human Malaria Infection Model for Evaluation of Transmission-Blocking Interventions - Study 1
This is a single-center, open label study. The primary aim of this project is to develop a controlled human malaria infection transmission model ("CHMI-trans") or "challenge model" to evaluate the capacity of vaccines, biologics…
- Trial name
- CHMI-trans1 (NCT02836002)
- Testing
- Sulfadoxine-pyrimethamine (low dose), Piperaquine (low dose), Sulfadoxine-pyrimethamine (high dose)
- Where
- Netherlands
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Falciparum Malaria
Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania
This is a phase Ib double-blind randomized placebo controlled age-deescalating trial to assess sagety and immunogenicity of two virosome formulated anti-malaria vaccine components (PEV 301 and PEV 302) administered in combination…
- Trial name
- PMAL03 (NCT00513669)
- Testing
- PEV 301& 302 in virosomes, Inflexal V (active comparator)
- Where
- Tanzania
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Swiss Tropical & Public Health Institute
Malaria, Schistosomiasis
Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana
The purpose of this study is to determine if Artemisinin-based Combination Therapy, ACT,(artemether-lumefantrine) used as intermittent preventive treatment (IPT) alone or in combination with praziquantel, will have any effects on…
- Conditions
- Malaria, Schistosomiasis, Helminthiasis, Anemia
- Trial name
- ACTIPT (NCT01459146)
- Testing
- Artemether-lumefantrine combination plus albendazole, Artemether-lumefantrine plus Praziquantel plus Albendazole, Albendazole plus Praziquantel
- Where
- Ghana
- Volunteers
- 345 people
- Sponsor
- Navrongo Health Research Centre, Ghana
Plasmodium Falciparum Malaria
Assessment of Three Formulations of the Candidate Vaccine AMA 1 in Healthy Dutch Adult Volunteers
The objective of this study was to evaluate the safety of a candidate malaria vaccine (PfAMA-1) at 3 doses given at monthly intervals of 2 different dosages of AMA-1 (10 μg or 50 μg ) adjuvanted either with alum hydroxide or…
- Trial name
- NCT00730782
- Testing
- PfAMA-1-FVO[25-545]
- Where
- 2 sites in Netherlands
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- European Vaccine Initiative
Prevention of Malaria Transmission and Clinical Malaria
Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults
This is a Phase 1, individually randomized, double-blind, dose escalating study designed to evaluate the safety, tolerability, and immunogenicity of Pfs230D1 conjugate vaccines, R21 nanoparticle vaccine, or their combination…
- Trial name
- NCT06507605
- Testing
- R21, Pfs230D1-CRM197, Pfs230D1-EPA
- Where
- Mali
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Malaria
Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A : Phase Ia/Ib
P27A study is designed as a randomized phase Ia/Ib trial to evaluate the safety and immunogenicity of the blood stage candidate vaccine P27A against P.
- Trial name
- P27A (NCT01949909)
- Testing
- CH-Alum50, CH-GLA2.5/50, TZ Ver
- Where
- 2 sites in Switzerland, Tanzania
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Plasmodium Falciparum Malaria
EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria
Malaria, a disease responsible for over one million deaths per year, is caused by a germ spread by mosquito bites. The purpose of this study is to evaluate a vaccine designed for the prevention of malaria caused by the parasite…
- Trial name
- NCT01169077
- Testing
- EP-1300
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Malaria, Falciparum
Mass Drug Administration With Dihydroartemisinin + Piperaquine for Reducing Malaria in Southern Zambia
To quantify the relative effectiveness, cost, and cost-effectiveness of fMDA and MDA with DHAp against no mass treatment for reducing P.
- Trial name
- NCT02329301
- Testing
- MDA with DHAp (Eurartesim), Focal MDA with DHAp (Eurartesim)
- Where
- Zambia
- Volunteers
- 2,430 people, healthy volunteers welcome
- Sponsor
- PATH
Malaria, Falciparum
Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S
The purpose of this study is to see if two new malaria vaccines called FMP1 and RTSS, combined with an adjuvant (called SBAS2) which helps stimulate the body's immune system, are safe, demonstrate an immune response through blood…
- Trial name
- MAL019 (NCT01556945)
- Testing
- FMP1/AS02, RTS,S/AS02, AS02 adjuvant alone
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria
Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine
Background: Malaria is a disease that is spread by mosquitoes. Researchers are looking for a vaccine that can prevent mosquitoes from transmitting malaria to people.
- Trial name
- NCT01867463
- Testing
- Pfs25-EPA/Alhydrogel, Euvax B, Menactra
- Where
- Mali
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diabetes Mellitus, Type 2, Obesity
Association of Diabetes and Metabolic Syndrome With Severe Malaria in Cameroon
The aim of this study is to investigate if diabetes, obesity and metabolic syndrome affects disease presentation and severity of malaria in adults in a hospital setting in Cameroon.
- Conditions
- Diabetes Mellitus, Type 2, Obesity, Metabolic Syndrome, Severe Malaria
- Trial name
- NCT05685875
- Testing
- diabetes
- Where
- 2 sites in Cameroon
- Volunteers
- 300 people
- Sponsor
- Karolinska Institutet
Plasmodium Falciparum
Efficacy and Safety of a Single Low-dose Primaquine for the Clearance of Gametocytes
The purpose of this study is to assess efficacy and safety of a single low-dose Primaquine added to standard artemether/lumefantrine treatment for the clearance of Plasmodium falciparum gametocytes among patients with…
- Trial name
- NCT02090036
- Testing
- Primaquine (For artemether-lumefantrine+primaquine arm)
- Where
- Tanzania
- Volunteers
- 220 people
- Sponsor
- Muhimbili University of Health and Allied Sciences
Malaria, Mosquito-Borne Disease
Evaluation of the Protective Efficacy of a Spatial Repellent to Reduce Malaria Prevalence in Uganda
A cluster-randomized double-blinded control trial will be conducted in Uganda to demonstrate and quantify the protective efficacy (PE) of Mossie-GO, an active spatial repellent system disseminating transfluthrin, in reducing the…
- Trial name
- Mossie-GO (NCT06232954)
- Testing
- Mossie-Go containing treated transfluthrin disc, Mossie-Go containing untreated blank disc
- Where
- Uganda
- Volunteers
- 5,600 people, healthy volunteers welcome
- Sponsor
- Africa Power Limited
Plasmodium Falciparum Infection
Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of Three or Five Administrations of GAP3KO Sporozoites
This Phase 1 trial will include 16 subjects who will receive the Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum Parasites (GAP3KO) vaccine administered by the bite of approximately 200 infected Anopheles stephensi…
- Trial name
- NCT03168854
- Testing
- Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum parasite (GAP3KO) strain, Malaria challenge
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Uncomplicated Plasmodium Falciparum Malaria
Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria
This study aims to confirm the efficacy, safety and tolerability of KLU156, a fixed dose combination of ganaplacide (KAF156) and a solid dispersion formulation of lumefantrine (lumefantrine-SDF), when administered once daily for…
- Trial name
- KALUMA (NCT05842954)
- Testing
- KLU156, Coartem
- Where
- 33 sites in Burkina Faso, Côte d’Ivoire and 10 more
- Volunteers
- 1,720 people
- Sponsor
- Novartis Pharmaceuticals
Malaria
Mass Drug Administrations of DHA-PQP to Accelerate Towards Malaria Elimination in Magude District, Southern Mozambique
In line with the global and regional efforts towards malaria elimination, a five year program was established to assist the NMCP in adopting targeted evidence-based elimination plans through a 'learn by doing' strategy.
- Trial name
- MDAM (NCT02914145)
- Testing
- Dihydroartemisinin-piperaquine
- Volunteers
- 240,502 people, healthy volunteers welcome
- Sponsor
- Centro de Investigacao em Saude de Manhica
Malaria
Pyronaridine-artesunate and Artemether-lumefantrine for the Treatment of Paediatric Malaria
The purpose of this study is to determine the efficacy of pyronaridine-artesunate and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children.
- Trial name
- PAAL (NCT02411994)
- Testing
- Pyronaridine-artesunate, Artemether-lumefantrine combination
- Where
- Kenya
- Volunteers
- 197 people
- Sponsor
- Royal Tropical Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.